Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin adjunctive therapy for schizophrenia
2012-004504-35Phase 2Completed
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
- Start
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in schizophrenia (2 arms), sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Primary endpoint: PANSS negative score change. Started Apr 2013; status: completed.
02
Drugs
oxytocin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2012-004504-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004504-35.